Compass Therapeutics (CMPX) Total Liabilities (2018 - 2026)

Compass Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 11.69% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $18.7 million (down 11.69% YoY), while the FY2025 annual figure was $22.8 million, up 50.28% from the prior year.
• Total Liabilities came in at $18.7 million for Q1 2026 at Compass Therapeutics, down from $22.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $23.5 million in Q2 2025 to a low of $4.1 million in Q1 2024.
• A 5-year average of $14.4 million and a median of $12.7 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities tumbled 67.88% in 2024 and surged 418.67% in 2025, its largest moves.
• Compass Therapeutics' Total Liabilities stood at $18.0 million in 2022, then plunged by 53.7% to $8.3 million in 2023, then soared by 81.96% to $15.2 million in 2024, then surged by 50.28% to $22.8 million in 2025, then dropped by 17.98% to $18.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $18.7 million, $22.8 million, and $21.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison